Evelo Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Evelo Biosciences is de winst gegroeid met een gemiddeld jaarlijks percentage van 31.2%, terwijl de Biotechs industrie de winst growing met 19.3% per jaar.

Belangrijke informatie

31.2%

Groei van de winst

70.6%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	n/a
Nettomarge	n/a
Laatste winstupdate	30 Sep 2023

Recente prestatie-updates uit het verleden

Recent updates

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

Mar 11

Evelo Bio secures ~$67.5M capital raise

Jan 29

Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis

Jan 07

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Dec 15

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

Dec 11

Evelo Biosciences identifies new lead oncology candidate

Dec 09

Evelo Bio's EDP1815 completes enrollment targeting interim data in mid-stage psoriasis study

Dec 03

Evelo Biosciences EPS beats by $0.04

Oct 29

Opbrengsten en kosten

Hoe Evelo Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:EVLO Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 23	-82	19	52
30 Jun 23	-101	23	67
31 Mar 23	-110	28	77
31 Dec 22	-115	30	79
30 Sep 22	-120	34	81
30 Jun 22	-123	37	82
31 Mar 22	-124	35	81
31 Dec 21	-122	32	84
30 Sep 21	-123	29	87
30 Jun 21	-110	24	79
31 Mar 21	-99	22	74
31 Dec 20	-94	22	70
30 Sep 20	-87	22	64
30 Jun 20	-88	23	65
31 Mar 20	-88	24	65
31 Dec 19	-85	23	63
30 Sep 19	-78	22	58
30 Jun 19	-73	21	54
31 Mar 19	-68	20	48
31 Dec 18	-61	18	40
30 Sep 18	-55	16	35
30 Jun 18	-49	13	29
31 Mar 18	-40	9	23
31 Dec 17	-34	8	20

Kwaliteitswinsten: EVLO is momenteel verliesgevend.

Groeiende winstmarge: EVLO is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: Er zijn onvoldoende gegevens om te bepalen of de jaarlijkse winstgroei van EVLO de afgelopen 5 jaar positief was.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van EVLO over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: EVLO is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van EVLO zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Evelo Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Evelo Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Evelo Biosciences, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Evelo Biosciences, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Recent updates

Evelo Biosciences, Inc. Files Form 15

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index

Evelo Biosciences Provides Non-Compliance Update

Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis

Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering

Evelo Biosciences, Inc. Announces Management Changes

Evelo Biosciences, Inc. Announces Management Changes

Evelo Biosciences Announces Reverse Stock Split to Meet the Minimum Per Share Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

Evelo Biosciences, Inc. Eliminates Position of Jonathan Zung, Chief Development Officer

David R. Epstein Intends to Resign from Evelo Biosciences, Inc.'s Board

Evelo Biosciences, Inc. Announces Executive Changes

Evelo Biosciences, Inc. Announces Updates to its Clinical Pipeline

Price target decreased to US$8.00

High number of new directors

Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?

Evelo Biosciences, Inc. Plans to Replace President Simba Gill

Evelo Biosciences, Inc. Announces Two Phase 2 Clinical Read-Outs with EDP1815 in Atopic Dermatitis Expected in First quarter and Second Quarter 2023; Phase 2 Data for EDP2939 in Psoriasis expected in Second Half 2023

Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03

Evelo Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Evelo Biosciences, Inc. Appoints Marella Thorell as the Chief Financial Officer Effective from September 1, 2022

Marella Thorell is the new finance chief of Evelo Biosciences

Evelo Biosciences, Inc.(NasdaqGS:EVLO) dropped from Russell 2000 Dynamic Index

Evelo Biosciences: Hope After Dilution?

Evelo Biosciences, Inc. Announces Executive Changes

High number of new directors

High number of new directors

Price target decreased to US$15.40

David P. Perry Not Stand for Re-Election to Board of Directors of Evelo Biosciences, Inc

Evelo Biosciences, Inc. Plans to Meet with Health Authorities to Discuss the Path Forward to Registration Trials for EDP1815 in Patients with Psoriasis

Price target increased to US$22.50

Evelo Biosciences, Inc. Announces Executive Appointments

Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?

Evelo Biosciences, Inc. Announces Data from Post-Treatment Follow-Up (Part B) of its Phase 2 Trial of EDP1815 in Mild and Moderate Psoriasis

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in Edp1815 Phase 2 Psoriasis Trial

Price target increased to US$23.70

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

Evelo Biosciences, Inc. Announces Updates of Phase 2 Clinical Trial of EDP1815 in Atopic Dermatitis and Phase 1B Clinical Data with EDP1815 in Atopic Dermatitis

High number of new directors

High number of new directors

Evelo Biosciences, Inc. Announces Positive Data from Its Phase 2 Study Evaluating EDP1815 Versus Placebo for the Treatment of Mild and Moderate Psoriasis

Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?

Price target increased to US$23.33

Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-Inflammatory Product Candidate Edp2939 at the American Association of Immunologists Meeting

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

Evelo Biosciences, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Appoints John A. Hohneker, M.D. to Board of Directors

Evelo Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $67.5 million.

Evelo Bio secures ~$67.5M capital raise

New 90-day high: US$18.60

Evelo Biosciences, Inc. Updates Data Following Completion of the Mild and Moderate Atopic Dermatitis Cohort in Its Phase 1B Clinical Trial

New 90-day high: US$13.89

Evelo Biosciences Expands Clinical Programs

Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis

New 90-day high: US$12.28

Evelo Biosciences, Inc. Appoints Jonathan Zung as Chief Development Officer

Evelo Biosciences, Inc. Enters into Development and Clinical Master Services Agreement with Halo Pharmaceutical, Inc

Evelo Biosciences, Inc. Updates on Its Clinical Trails

Independent Chairman recently bought US$51k worth of stock

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Evelo Biosciences, Inc. Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

Price target raised to US$9.67

New 90-day high: US$6.41

Evelo Biosciences identifies new lead oncology candidate

Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis

Evelo Bio's EDP1815 completes enrollment targeting interim data in mid-stage psoriasis study

Price target lowered to US$9.00

Evelo Biosciences, Inc. Announces Preclinical Data for EDP1908

Evelo Biosciences EPS beats by $0.04

Evelo Biosciences, Inc. Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis